Human Metapneumovirus (hMPV) Diagnostics Market was valued at USD 491.24 million in 2023 and is expected to reach USD 1201.37 million by 2032, growing at a CAGR of 10.39% from 2024 to 2032.
The Human Metapneumovirus (hMPV) Diagnostics Market report provides exclusive insights by concentrating on incidence and prevalence trends in major regions in 2023, including seasonal patterns and vulnerable populations. It comprehensively analyzes healthcare expenditure on hMPV diagnostics, categorized by government, commercial, private, and out-of-pocket spending. The report also delves into regulatory and technological developments influencing the market, such as AI-based diagnostics and multiplex testing. In addition, trends in volume and use of diagnostic testing by region are examined, providing a comparative estimate of hospital, diagnostic laboratory, and point-of-care market penetration.
The U.S. Human Metapneumovirus (hMPV) Diagnostics Market size was USD 139.41 million in 2023 and is expected to reach USD 332.69 million by 2032, growing at a CAGR of 10.09% over the forecast period of 2024-2032.
The market is driven by increasing awareness of respiratory infections and the rising prevalence of hMPV-related illnesses, particularly in young children and elderly populations. Advancements in diagnostic technologies, such as rapid molecular assays and PCR-based testing, are enhancing early detection and treatment. Growing investments in healthcare infrastructure and research on respiratory viruses further contribute to market expansion. Additionally, the surge in demand for point-of-care testing and the development of innovative diagnostic solutions are expected to fuel market growth.
Drivers
Rising Awareness and Increasing Diagnostic Testing for Respiratory Infections are propelling the market growth.
The increasing need for respiratory virus awareness, especially post-COVID-19, has increased testing for Human Metapneumovirus (hMPV) considerably. As clinical symptoms resemble RSV and influenza, the demand is rising for timely and precise diagnosis to differentiate hMPV from other infections. The CDC says that hMPV cases are at their peak in the late winter and spring seasons, creating seasonality in the volume of tests. The latest developments in multiplex diagnostic panels, which identify hMPV in addition to other respiratory viruses, have also stimulated market growth. For example, in 2023, QuidelOrtho and bioMérieux introduced sophisticated molecular diagnostic tests that enhanced accuracy and minimized turnaround time. In addition, government programs, including the widening of respiratory disease surveillance programs in the United States and Europe, are driving the use of hMPV diagnostic solutions in clinical and point-of-care environments.
Technological Advancements in Molecular Diagnostics and AI Integration are driving the market to grow.
The advancement of molecular diagnostics, AI-based testing, and automation is dramatically improving hMPV detection efficiency. New-generation PCR-based tests now provide increased sensitivity and specificity, minimizing false negatives. For example, in 2023, Seegene launched a real-time PCR respiratory panel that identifies hMPV along with 20 other viruses, enhancing diagnostic accuracy. Moreover, AI-based diagnostics are streamlining test interpretation and decreasing turnaround times. Firms such as Roche and Thermo Fisher Scientific have incorporated AI algorithms into diagnostic platforms, facilitating quicker detection and automated reporting. Market growth is also being driven by the growing use of point-of-care and home-based diagnostic solutions like lateral flow assays and portable PCR instruments. With repeated FDA and CE approvals for novel diagnostic kits, advances in technology are poised to further transform the hMPV diagnostics market.
Restraint
High Cost and Limited Accessibility of Advanced Diagnostic Tests are restraining the market to grow.
High cost incurred in molecular diagnostic tests, especially PCR-based and multiplex assays, is one of the key constraints in the Human Metapneumovirus (hMPV) Diagnostics Market. Although these tests provide better sensitivity and specificity, their high equipment, reagent, and maintenance costs make them inaccessible, mainly in low- and middle-income countries (LMICs). As per recent healthcare reports, the price of PCR-based respiratory virus panels is between USD 100 and USD 300 per test, which is economically expensive for patients without insurance. Moreover, in many rural and underdeveloped areas, the absence of proper laboratory facilities and trained personnel further inhibits market growth. While firms are investing in portable and affordable diagnostic solutions, widespread affordability is still a problem. Reimbursement restrictions and regulatory challenges in different regions also account for limited adoption rates.
Opportunities
The increased need for speedy, decentralized, and affordable diagnostic products is a major opportunity within the Human Metapneumovirus (hMPV) Diagnostics Market.
Point-of-care (POC) and home-based testing kits are increasingly gaining popularity, especially in areas with poor access to centralized labs. Firms such as Abbott and Hangzhou Testsea Biotechnology are working tirelessly on developing portable PCR machines and lateral flow tests for rapid detection of hMPV outside formal healthcare facilities. Following industry dynamics, the usage of home-based respiratory testing kits across the world has increased enormously since the pandemic, with doctors putting a spotlight on early detection to avert extreme complications. Regulatory agencies, such as the FDA and EMA, are clearing next-generation POC diagnostics, offering new market opportunities. The growing use of AI-based mobile apps for the interpretation of test results increases the potential even further.
Challenges
Differentiation of hMPV from Other Respiratory Infections is the key challenge for the market growth.
One of the major challenges in the hMPV diagnostics market is the challenge of differentiating hMPV from other respiratory viruses, such as RSV, influenza, and COVID-19, since they present with similar clinical symptoms. Lack of distinctive symptoms mostly causes misdiagnosis or a hold-up in the test, which affects patient outcomes and market adoption. Healthcare professionals often prefer testing for more established viruses, which restrains hMPV test usage. Though multiplex diagnostic panels that can identify several pathogens are becoming increasingly popular, their exorbitant prices and availability in some regions are limiting widespread implementation. The inconsistencies in viral shedding patterns and false-negative outcomes with antigen-based tests also pose reliability concerns. Overcoming these issues needs to be through enhanced clinician awareness, higher sensitivity of tests, and creating low-cost multiplex solutions for making complete respiratory virus detection a reality.
By Technology
The PCR-based diagnostics market segment dominated the Human Metapneumovirus (hMPV) Diagnostics Market with 55.21% market share in 2023 because of its high specificity, sensitivity, and use across clinics. PCR-based tests, such as real-time and multiplex PCR, allow for hMPV to be detected in a short while and accurately in low viral load samples, rendering them the most preferred choice for respiratory virus diagnostics. Major players like Roche, Abbott, and Seegene have created sophisticated PCR panels that can detect several respiratory pathogens, including hMPV, simultaneously, further boosting the adoption of the segment. Furthermore, regulatory clearances and adoption into standard hospital diagnostic protocols have fortified the stronghold of PCR testing. Rising rates of hospital-acquired respiratory infections and the need for accurate diagnostics in immunocompromised patients also boosted the demand for PCR technology in 2023.
The Microarray Technology segment is anticipated to experience the fastest growth over the forecast years based on its capability to screen for several genetic markers at once, allowing for cost-effective and high-throughput diagnostics. With the increasing need for comprehensive respiratory virus panels, microarray-based platforms present a cost-effective solution for the simultaneous detection of hMPV as well as RSV, influenza, and SARS-CoV-2 in one test. Advances in bioinformatics and AI-driven data analysis have also increased the effectiveness of microarray diagnostics. Furthermore, research into portable microarray-based POC devices continues to improve accessibility in decentralized healthcare environments, especially in the emerging markets. Thermo Fisher Scientific and bioMérieux are among the firms investing in microarray innovation, making this technology a driver for the hMPV diagnostics of the future.
By End Use
The Clinics and Hospitals segment dominated the Human Metapneumovirus (hMPV) Diagnostics Market with a 52.14% market share in 2023 because they play a pivotal role in the diagnosis of respiratory infections and have greater patient traffic. Such facilities have the requisite infrastructure to accommodate sophisticated diagnostic tools such as PCR-based and multiplex assays, which are required for efficient and timely identification of hMPV. Hospitals and clinics are also the major healthcare providers for high-risk patients, such as pediatric and elderly patients, who are more vulnerable to hMPV infections. In addition, the adoption of molecular diagnostics into clinical practices and the growing need for quick diagnostic results in critical care have made hospitals and clinics the most prominent consumers of hMPV diagnostic tests in 2023.
The Diagnostic and Reference Laboratories business is experience to exhibit the fastest growth in the forecast years because of its niche orientation towards high-precision diagnostic testing and high throughput. These laboratories are embracing multiplex diagnostic panels and next-generation sequencing (NGS) more and more to detect multiple pathogens, such as hMPV, from patient samples simultaneously. With the growth in national and regional diagnostic reference labs, particularly across emerging economies, there is also an increasing requirement for centralized facilities for testing capable of delivering quick and complete test results. Also, collaborations among diagnostic firms and reference labs in performing large-volume clinical trials as well as surveillance studies, will catalyze the mounting adoption of testing for hMPV in the reference labs and hence their sudden growth during the forecast period.
Regional Analysis
North America dominated the Human Metapneumovirus (hMPV) Diagnostics Market with a 39.24% market share in 2023, owing to its developed healthcare infrastructure, high level of diagnostic awareness, and robust government funding for the detection of respiratory viruses. The United States is the leader in the region, with the CDC regularly tracking hMPV trends and encouraging diagnostic testing. The availability of large diagnostic firms such as Abbott, Roche, and Thermo Fisher Scientific further reinforces market leadership, as these companies continuously launch advanced PCR-based and multiplex assays. Moreover, the general availability of insurance coverage and reimbursement policies for respiratory testing further increases accessibility. The region also experiences high rates of adoption of molecular diagnostics and point-of-care testing in hospitals, clinics, and home-based environments. Regulatory clearances, including FDA approvals of novel diagnostic panels, remain to fuel North America's market leadership.
Asia Pacific is the hMPV Diagnostics Market's fastest-growing region with 11.00% CAGR throughout the forecast period, fueled by increased respiratory infections, expanding healthcare expenditure, and heightened virus detection consciousness. China, India, and Japan are witnessing an explosion in demand for diagnostic testing fueled by the growing pediatric and geriatric populations, who are most susceptible to hMPV infections. Government programs, including increased infectious disease surveillance programs and incentives for diagnostic innovations, are driving market growth. Local diagnostic firms are also creating affordable and speedy testing options, which are bringing diagnostics to emerging economies within reach. Growing uptake of portable molecular diagnostic equipment and AI-based healthcare technologies is further driving market growth. The existence of densely populated areas with an increasing burden of respiratory disease places the Asia Pacific as the most rapidly expanding market for hMPV diagnostics.
QuidelOrtho Corporation (Lyra RSV + hMPV Assay, Solana RSV + hMPV Assay)
ARUP Laboratories (Respiratory Virus PCR Panel, hMPV Direct Detection Test)
DiaSorin (Simplexa hMPV Direct Assay, LIAISON hMPV IgG)
R-Biopharm AG (RIDA GENE hMPV, RIDA QUICK hMPV)
Seegene Inc. (Allplex Respiratory Panel Assay, Anyplex II RV16 Detection)
ZeptoMetrix (NATtrol hMPV Stock, hMPV Antigen)
Abbott (RealTime hMPV Assay, Alinity m Resp-4-Plex)
Thermo Fisher Scientific Inc. (TaqMan hMPV Assay, Invitrogen hMPV Antibodies)
Tianlong (Human Metapneumovirus PCR Detection Kit, Gentier Real-Time PCR Systems)
Hangzhou Testsea Biotechnology Co., Ltd. (hMPV Rapid Test Kit, Testsealabs hMPV Antigen Test)
Attogene (Human Metapneumovirus Advanced Kit, oasig Lyophilised OneStep RT-qPCR Master Mix)
The Native Antigen Company (hMPV 18 Type B2 Lysate, Mouse Anti-hMPV Antibody)
bioMérieux (BioFire Respiratory Panel, VIDAS hMPV Assay)
Qiagen (QIAstat-Dx Respiratory Panel, artus hMPV RG RT-PCR Kit)
Hologic, Inc. (Aptima Respiratory Assay, Panther Fusion hMPV Assay)
Roche Diagnostics (cobas Liat Respiratory Panel, LightMix Modular hMPV Assay)
PerkinElmer (NGEN Respiratory Pathogen Panel, hMPV RT-PCR Kit)
Luminex Corporation (NxTAG Respiratory Pathogen Panel, ARIES hMPV Assay)
GenMark Diagnostics (ePlex Respiratory Pathogen Panel, XT-8 Respiratory Viral Panel)
Cepheid (Xpert Xpress Flu/RSV/hMPV, GeneXpert hMPV Assay)
Suppliers (These suppliers provide essential components such as nucleic acid extraction kits, PCR reagents, enzymes, primers, probes, and antibodies, which are crucial for manufacturing hMPV diagnostic assays.) in Human Metapneumovirus (hMPV) Diagnostics Market
Merck KGaA
Thermo Fisher Scientific
New England Biolabs
Bio-Rad Laboratories
Promega Corporation
Takara Bio Inc.
Roche CustomBiotech
Integrated DNA Technologies (IDT)
LGC Biosearch Technologies
Agilent Technologies
In November 2023, RIDA®UNITY RSV & hMPV was introduced for use on the RIDA®UNITY Platform. This multiplex real-time RT-PCR test allows for direct qualitative detection and discrimination of respiratory syncytial virus (A/B) and human metapneumovirus (A/B) RNA in untreated human nasal/throat swabs and bronchoalveolar lavage (BAL) specimens from symptomatic individuals with acute respiratory infection.
In July 2022, Thermo Fisher Scientific launched Applied Biosystems TaqPath Respiratory Viral Select Panel, a CE-IVD-certified molecular assay that can detect five common respiratory viruses, namely human metapneumovirus (hMPV), facilitating respiratory disease diagnostics.
| Report Attributes | Details |
|---|---|
| Market Size in 2023 | US$ 491.24 million |
| Market Size by 2032 | US$ 1201.37 million |
| CAGR | CAGR of 10.39% from 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Technology (PCR-Based Diagnostics, Next-Generation Sequencing (NGS), Immunofluorescence Assays, Lateral Flow Assays, Microarray Technology, Other Advanced Technologies) • By End Use (Hospitals and Clinics, Diagnostic and Reference Laboratories, Academic and Research Institutions, Others) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
| Company Profiles | QuidelOrtho Corporation, ARUP Laboratories, DiaSorin, R-Biopharm AG, Seegene Inc., ZeptoMetrix, Abbott, Thermo Fisher Scientific Inc., Tianlong, Hangzhou Testsea Biotechnology Co., Ltd., Attogene, The Native Antigen Company, bioMérieux, Qiagen, Hologic, Inc., Roche Diagnostics, PerkinElmer, Luminex Corporation, GenMark Diagnostics, Cepheid, and other players. |
Ans: The Human Metapneumovirus (hMPV) Diagnostics Market is expected to grow at a CAGR of 10.39% from 2024 to 2032.
Ans: The Human Metapneumovirus (hMPV) Diagnostics Market was USD 491.24 million in 2023 and is expected to reach USD 1201.37 million by 2032.
Ans: Technological Advancements in Molecular Diagnostics and AI Integration are driving the market to grow.
Ans: The “Hospitals and Clinics” segment dominated the Human Metapneumovirus (hMPV) Diagnostics Market.
Ans: North America dominated the Human Metapneumovirus (hMPV) Diagnostics Market in 2023.
Table of Contents:
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.2 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
5. Statistical Insights and Trends Reporting
5.1 Incidence and Prevalence of hMPV Infections (2023)
5.2 Healthcare Spending on hMPV Diagnostics, by Region (Government, Commercial, Private, Out-of-Pocket), 2023
5.3 Regulatory and Technological Trends in hMPV Diagnostics (2023-2032)
5.4 Diagnostic Testing Volume and Utilization Trends (2023), by Region
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Human Metapneumovirus (hMPV) Diagnostics Market Segmentation, By Technology
7.1 Chapter Overview
7.2 PCR-Based Diagnostics
7.2.1 PCR-Based Diagnostics Market Trends Analysis (2020-2032)
7.2.2 PCR-Based Diagnostics Market Size Estimates and Forecasts to 2032 (USD Million)
7.3 Next-Generation Sequencing (NGS)
7.3.1 Next-Generation Sequencing (NGS) Market Trends Analysis (2020-2032)
7.3.2 Next-Generation Sequencing (NGS) Market Size Estimates and Forecasts to 2032 (USD Million)
7.4 Immunofluorescence Assays
7.4.1 Immunofluorescence Assays Market Trends Analysis (2020-2032)
7.4.2 Immunofluorescence Assays Market Size Estimates and Forecasts to 2032 (USD Million)
7.5 Lateral Flow Assays
7.5.1 Lateral Flow Assays Market Trends Analysis (2020-2032)
7.5.2 Lateral Flow Assays Market Size Estimates and Forecasts to 2032 (USD Million)
7.6 Microarray Technology
7.6.1 Microarray Technology Market Trends Analysis (2020-2032)
7.6.2 Microarray Technology Market Size Estimates and Forecasts to 2032 (USD Million)
7.7 Other Advanced Technologies
7.7.1 Other Advanced Technologies Market Trends Analysis (2020-2032)
7.7.2 Other Advanced Technologies Market Size Estimates and Forecasts to 2032 (USD Million)
8. Human Metapneumovirus (hMPV) Diagnostics Market Segmentation, by End User
8.1 Chapter Overview
8.2 Hospitals & Clinics
8.2.1 Hospitals & Clinics Market Trends Analysis (2020-2032)
8.2.2 Hospitals & Clinics Market Size Estimates and Forecasts to 2032 (USD Million)
8.3 Diagnostic and Reference Laboratories
8.3.1 Long-term Care Centers Market Trends Analysis (2020-2032)
8.3.2 Long-term Care Centers Market Size Estimates and Forecasts to 2032 (USD Million)
8.4 Academic and Research Institutions
8.4.1 Academic and Research Institutions Market Trends Analysis (2020-2032)
8.4.2 Academic and Research Institutions Market Size Estimates and Forecasts to 2032 (USD Million)
8.5 Others
8.5.1 Other Market Trends Analysis (2020-2032)
8.5.2 Others Market Size Estimates and Forecasts to 2032 (USD Million)
9. Regional Analysis
9.1 Chapter Overview
9.2 North America
9.2.1 Trends Analysis
9.2.2 North America Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
9.2.3 North America Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by Technology (2020-2032) (USD Million)
9.2.4 North America Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.2.5 USA
9.2.5.1 USA Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by Technology (2020-2032) (USD Million)
9.2.5.2 USA Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.2.6 Canada
9.2.6.1 Canada Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by Technology (2020-2032) (USD Million)
9.2.6.2 Canada Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.2.7 Mexico
9.2.7.1 Mexico Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by Technology (2020-2032) (USD Million)
9.2.7.2 Mexico Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.3 Europe
9.3.1 Eastern Europe
9.3.1.1 Trends Analysis
9.3.1.2 Eastern Europe Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
9.3.1.3 Eastern Europe Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by Technology (2020-2032) (USD Million)
9.3.1.4 Eastern Europe Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.3.1.5 Poland
9.3.1.5.1 Poland Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by Technology (2020-2032) (USD Million)
9.3.1.5.2 Poland Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.3.1.6 Romania
9.3.1.6.1 Romania Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by Technology (2020-2032) (USD Million)
9.3.1.6.2 Romania Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.3.1.7 Hungary
9.3.1.7.1 Hungary Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by Technology (2020-2032) (USD Million)
9.3.1.7.2 Hungary Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.3.1.8 Turkey
9.3.1.8.1 Turkey Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by Technology (2020-2032) (USD Million)
9.3.1.8.2 Turkey Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.3.1.9 Rest of Eastern Europe
9.3.1.9.1 Rest of Eastern Europe Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by Technology (2020-2032) (USD Million)
9.3.1.9.2 Rest of Eastern Europe Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.3.2 Western Europe
9.3.2.1 Trends Analysis
9.3.2.2 Western Europe Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
9.3.2.3 Western Europe Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by Technology (2020-2032) (USD Million)
9.3.2.4 Western Europe Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.3.2.5 Germany
9.3.2.5.1 Germany Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by Technology (2020-2032) (USD Million)
9.3.2.5.2 Germany Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.3.2.6 France
9.3.2.6.1 France Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by Technology (2020-2032) (USD Million)
9.3.2.6.2 France Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.3.2.7 UK
9.3.2.7.1 UK Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by Technology (2020-2032) (USD Million)
9.3.2.7.2 UK Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.3.2.8 Italy
9.3.2.8.1 Italy Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by Technology (2020-2032) (USD Million)
9.3.2.8.2 Italy Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.3.2.9 Spain
9.3.2.9.1 Spain Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by Technology (2020-2032) (USD Million)
9.3.2.9.2 Spain Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.3.2.10 Netherlands
9.3.2.10.1 Netherlands Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by Technology (2020-2032) (USD Million)
9.3.2.10.2 Netherlands Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.3.2.11 Switzerland
9.3.2.11.1 Switzerland Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by Technology (2020-2032) (USD Million)
9.3.2.11.2 Switzerland Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.3.2.12 Austria
9.3.2.12.1 Austria Healthcare Predictive Analytic Market Estimates and Forecasts, by Technology (2020-2032) (USD Million)
9.3.2.12.2 Austria Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.3.2.13 Rest of Western Europe
9.3.2.13.1 Rest of Western Europe Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by Technology (2020-2032) (USD Million)
9.3.2.13.2 Rest of Western Europe Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.4 Asia Pacific
9.4.1 Trends Analysis
9.4.2 Asia Pacific Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
9.4.3 Asia Pacific Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by Technology (2020-2032) (USD Million)
9.4.4 Asia Pacific Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.4.5 China
9.4.5.1 China Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by Technology (2020-2032) (USD Million)
9.4.5.2 China Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.4.6 India
9.4.5.1 India Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by Technology (2020-2032) (USD Million)
9.4.5.2 India Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.4.5 Japan
9.4.5.1 Japan Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by Technology (2020-2032) (USD Million)
9.4.5.2 Japan Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.4.6 South Korea
9.4.6.1 South Korea Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by Technology (2020-2032) (USD Million)
9.4.6.2 South Korea Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.4.7 Vietnam
9.4.7.1 Vietnam Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by Technology (2020-2032) (USD Million)
9.2.7.2 Vietnam Healthcare Predictive Analytic Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.4.8 Singapore
9.4.8.1 Singapore Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by Technology (2020-2032) (USD Million)
9.4.8.2 Singapore Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.4.9 Australia
9.4.9.1 Australia Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by Technology (2020-2032) (USD Million)
9.4.9.2 Australia Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.4.10 Rest of Asia Pacific
9.4.10.1 Rest of Asia Pacific Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by Technology (2020-2032) (USD Million)
9.4.10.2 Rest of Asia Pacific Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.5 Middle East and Africa
9.5.1 Middle East
9.5.1.1 Trends Analysis
9.5.1.2 Middle East Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
9.5.1.3 Middle East Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by Technology (2020-2032) (USD Million)
9.5.1.4 Middle East Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.5.1.5 UAE
9.5.1.5.1 UAE Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by Technology (2020-2032) (USD Million)
9.5.1.5.2 UAE Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.5.1.6 Egypt
9.5.1.6.1 Egypt Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by Technology (2020-2032) (USD Million)
9.5.1.6.2 Egypt Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.5.1.7 Saudi Arabia
9.5.1.7.1 Saudi Arabia Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by Technology (2020-2032) (USD Million)
9.5.1.7.2 Saudi Arabia Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.5.1.8 Qatar
9.5.1.8.1 Qatar Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by Technology (2020-2032) (USD Million)
9.5.1.8.2 Qatar Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.5.1.9 Rest of Middle East
9.5.1.9.1 Rest of Middle East Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by Technology (2020-2032) (USD Million)
9.5.1.9.2 Rest of Middle East Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.5.2 Africa
9.5.2.1 Trends Analysis
9.5.2.2 Africa Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
9.5.2.3 Africa Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by Technology (2020-2032) (USD Million)
9.5.2.4 Africa Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.5.2.5 South Africa
9.5.2.5.1 South Africa Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by Technology (2020-2032) (USD Million)
9.5.2.5.2 South Africa Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.5.2.6 Nigeria
9.5.2.6.1 Nigeria Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by Technology (2020-2032) (USD Million)
9.5.2.6.2 Nigeria Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.5.2.7 Rest of Africa
9.5.2.7.1 Rest of Africa Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by Technology (2020-2032) (USD Million)
9.5.2.7.2 Rest of Africa Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.6 Latin America
9.6.1 Trends Analysis
9.6.2 Latin America Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
9.6.3 Latin America Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by Technology (2020-2032) (USD Million)
9.6.4 Latin America Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.6.5 Brazil
9.6.5.1 Brazil Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by Technology (2020-2032) (USD Million)
9.6.5.2 Brazil Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.6.6 Argentina
9.6.6.1 Argentina Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by Technology (2020-2032) (USD Million)
9.6.6.2 Argentina Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.6.7 Colombia
9.6.7.1 Colombia Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by Technology (2020-2032) (USD Million)
9.6.7.2 Colombia Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
9.6.8 Rest of Latin America
9.6.8.1 Rest of Latin America Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by Technology (2020-2032) (USD Million)
9.6.8.2 Rest of Latin America Human Metapneumovirus (hMPV) Diagnostics Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10. Company Profiles
10.1 QuidelOrtho Corporation
10.1.1 Company Overview
10.1.2 Financial
10.1.3 Products/ Services Offered
110.1.4 SWOT Analysis
10.2 ARUP Laboratories
10.2.1 Company Overview
10.2.2 Financial
10.2.3 Products/ Services Offered
10.2.4 SWOT Analysis
10.3 DiaSorin
10.3.1 Company Overview
10.3.2 Financial
10.3.3 Products/ Services Offered
10.3.4 SWOT Analysis
10.4 R-Biopharm AG
10.4.1 Company Overview
10.4.2 Financial
10.4.3 Products/ Services Offered
10.4.4 SWOT Analysis
10.5 Seegene Inc.
10.5.1 Company Overview
10.5.2 Financial
10.5.3 Products/ Services Offered
10.5.4 SWOT Analysis
10.6 ZeptoMetrix
10.6.1 Company Overview
10.6.2 Financial
10.6.3 Products/ Services Offered
10.6.4 SWOT Analysis
10.7 Abbott
10.7.1 Company Overview
10.7.2 Financial
10.7.3 Products/ Services Offered
10.7.4 SWOT Analysis
10.8 Thermo Fisher Scientific Inc.
10.8.1 Company Overview
10.8.2 Financial
10.8.3 Products/ Services Offered
10.8.4 SWOT Analysis
10.9 Tianlong
10.9.1 Company Overview
10.9.2 Financial
10.9.3 Products/ Services Offered
10.9.4 SWOT Analysis
10.10 Hangzhou Testsea Biotechnology Co., Ltd.
10.9.1 Company Overview
10.9.2 Financial
10.9.3 Products/ Services Offered
10.9.4 SWOT Analysis
11. Use Cases and Best Practices
12. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Segments:
By Technology
PCR-Based Diagnostics
Next-Generation Sequencing (NGS)
Immunofluorescence Assays
Lateral Flow Assays
Microarray Technology
Other Advanced Technologies
By End Use
Hospitals and Clinics
Diagnostic and Reference Laboratories
Academic and Research Institutions
Others
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Detailed Volume Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Competitive Product Benchmarking
Geographic Analysis
Additional countries in any of the regions
Customized Data Representation
Detailed analysis and profiling of additional market players
The Transdermal Drug Delivery System Market size was USD 7.23 Billion in 2023 and is projected to grow to USD 10.77 Billion by 2032, with a CAGR of 4.54%.
The Dose Calibrator Market Size was valued at USD 1.5 Billion in 2023 and is expected to reach USD 2.1 Billion by 2032 and grow at a CAGR of 3.9% over the forecast period 2024-2032.
The Diabetes Devices Market Size was valued at USD 30.26 Billion in 2023, and is expected to reach USD 57.15 Billion by 2032, and grow at a CAGR of 7.66%.
The Pancreatic Cancer Treatment Market size was valued at USD 2.8 billion in 2023 and is expected to reach USD 10.53 billion by 2032 and grow at a CAGR of 15.85%.
The Hospital Capacity Management Solutions Market Size was valued at USD 4.17 billion in 2023 and expected to reach USD 14.85 billion by 2031 and grow at a CAGR of 17.2% over the forecast period 2024-2031.
The Wound Care Market size is expected to reach 33.99 billion by 2032 from USD 21.8 billion in 2023 and grow at a CAGR of 5.08% from 2024 to 2032.
Hi! Click one of our member below to chat on Phone
© 2025 All Rights Reserved by SNS Insider Pvt Ltd
